ABSTRACT: Recornbinant cldeno-as.sociclte~~ ' virus vectors 
One of major challenges that faces the field of gene therapy is the development of efficient and safe gene delivery systems.1 Recombinant adeno-associated virus (rAAV), an emerging member among current vector systems and already being tested in clinical trials," has several unique properties that make it attractive for use in somatic gene therapy. Unlike other viral vectors, rAAV vectors are derived from a nonpathogenic parvovirus and are able to transduce nondividing cells. In addition, they integrate in the host genome and allow long-term expression in transduced cells and their progeny, that makes rAAV vectors especially attractive for treating genetic diseases. Furthermore, unlike adenovirus vectors, rAAV vectors do not induce an immune that eliminates the transduced cells. Recent advances in the understanding of the basic biology of this vector and improved techniques allowing higher titer production of rAAV without contaminating helper adenovirus suggest a promising future for rAAV in gene therapy.
Thus far, in vivo studies with rAAV have demonstrated long-term and efficient gene transfer from a variety of tissues, including muscle, lung, brain, and liver. The liver is an important target organ for gene therapy for several reasons:
I. Many genetic disorders are the result of hepatic enzyme deficiencies that require liver-specific enzymes or cofactors that are needed for proper metabolic function. 2. The liver is a major synthetic organ and is responsible for production of a large number of circulating proteins. 3. Gene transfer into this organ may be the best way for achieving high-level production of hematogenously delivered proteins. 4. The liver is the only organ in the body besides bone marrow that can regenerate itself after partial ablation.
5.
The liver provides a large cellular target for direct in vivo gene transfer using intravenous infusion of cell specific vectors.
With the availablity of a number of disease models for preclinical testing, including factor VIII-and Factor IX-deficient canines and mouseh-8 models for hemophilia, the Watanabe rabbit for hypercholesterolemia, the Gunn rat for hyperbilirubinemia, and the Nagase analbuminemic rat, the liver represents an excellent target organ for gene therapy studies for genetic diseases. Excellent reviews of the biology and genetics of AAVy and the application of AAV vectors for gene therapy ll)-lh have been published. This review focuses on the recent developments, limitations, and potential applications of rAAV vectors for liver gene transfer. 
WILD-TYPE AAV BIOLOGY
Mediccrl Cmrer; Leidrrz, The Netherltmds, 'Ilepc~rtment of Pedicirric.~ crnd Genetics, Sttrnfbrcl Urrivrrsity Sc.hool ofMedicine, Stc~nfortl, Crrli-/orrritr adenovirusI7 or herpes simplex virusl". In the absence of a helper virus, AAV establishes a latent infection by integrating into the host genome, preferentially into a defined region of human chromosome 19 (AAVS 1 ). [19] [20] [21] If latently infected cells are subsequently infected with helper virus, AAV may be rescued from the integrated site in a process that requires excision and replication.
The AAV genome contains three promotors (p5, p19, p40), a single polyadenylation signal, nonstructural Rep genes, and the structural Cap gene flanked by 145-bp inverted terminal repeats (ITRs). which form a T-shaped hairpin secondary structure. The ITRs are the only cis-acting elements required for replication, packaging, and chromosomal integration of the AAV genome.".'? For a detailed review of the mechanisms of replication and integration of AAV, the reader is referred to reports by Muzyczka or Berns."'4,'5 Brietly, the 3'-OH end of the ITR-hairpin primes second-strand synthesis, leaving a double-stranded AAV genome with a covalently closed hairpin at one end. The structure is resolved by Rep-dependent nicking at the terminal resolution site, resulting in a linear duplex that is the substrate for a new replication round. Second-strand synthesis is required before gene expression can take place and also may be required for integration.zh.27 Viral integration is mediated by AAV-ITR-hairpin structures via nonviral cellular recombinantion pathways.23 Site-specific integration into chromosome 19 requires viral Rep proteins"-3[) and involves nonhomologous recombination.3' The viral genome is integrated as head-to-tail concatamers, whereas intermediates occurring during replication are head-to-head or tail-to-tail concatamers. Recently, the primary viral receptor for AAV type 2 was identified as heparan sulphate proteoglycan, which mediates both attachment to and infection of target cells.7'
RECOMBINANT

ADENO-ASSOCIATED VIRUS
The wild-type AAV does not allow insertion of foreign DNA due to size limitations of the packaged DNA. However, because gene transfer and (non-site-specific) integration can proceed in the absence of Rep proteins,'? recombinant AAV vectors have been developed by substituting all viral genes with a therapeutic minigene (up to 4.5 kb) while retaining the ITRs. A schematic representation of the production of rAAV is shown in Figure 1 .
The standard production method for rAAV is the two-plasmid (vectorlhelper) transient cotransfection system. The helper plasmid contains the AAV genes (Rep and Cap) necessary for replication and packaging but not the ITRs, whereas the rAAV vector plasmid contains the therapeutic gene flanked by the ITRs.3 Because the helper plasmid does not contain the AAV-ITR, the DNA will not be packaged, thus reducing the probability of homologous recombination and therefore the generation of wild-type AAV.34.3' The rAAV plasmid containing the therapeutic gene of interest and the AAV helper plasmid are cotransfected into cells (e.g., 293 or HeLa cells) and subsequently infected with helper adenovirus or plasmid encoding adenoviral genes. The helper plasmid will produce Rep and Cap proteins that in combination with adenoviral proteins excise, replicate, and package the rAAV DNA from the vector plasmid, resulting in AAV particles carrying either single strand-DNA copy of the therapeutic gene. Viral particles are purified from the supernatant by CsCl, density centrifugation to separate the adenovirus from the rAAV particles, followed by heat inactivation (at 56°C) to eliminate any residual adenovirus. The yields produced by these methods usually ranges between 100 and 1000 rAAV particles per cell. Recent studies demonstrated that coinfection with recombinant adenovirus can be replaced with plasmid DNAs encoding the critical adenoviral gene products.3hJ7
Functional virus titers are determined by infecting cell lines with recombinant virus and determining transgene expression (transducing unitslml)." Total viral particle titers can be determined using quantitative DNA dot blot hybridization (particleslml). Generally, the ratio is roughly in the range of one transducing unit to 500 to 1000 particles. The number of transducing units can vary greatly depending on the cell type used. Therefore, special attention should be given to the rAAV titers when interpreting rAAV gene transfer results. The presence of wild-type AAV contamination can be determined with a polymerase chain reactor assay or with a modified replication center assay,'Y as described by Snyder et al. 40 
PROPERTIES OF RAAV VECTORS
Recombinant adeno-associated virus has a number of advantages over other vector systems for gene therapy:
. The foremost advantage of rAAV vectors is safety.
The wild-type AAV is a defective parvovirus that requires helper virus infection to reproduce its progeny efficiently.17.18 More importantly, AAV is nonpathogenic and has no etiologic association with any known disease. 41 The removal of all viral coding sequences from the vector adds another safety feature that not only prevents the generation of wild-type helper virus, but also mitigates the possibility of an immune response against transduced cells caused by undesired viral gene expression,l() a significant problem seen with adenoviral vector ~ystems.42. Cap genes that, in combination with adenoviral proteins, excise, replicate, and package the rAAV DNAfrom the recombinant plasmid, resulting in AAV viral particles carrying the therapeutic gene. Because the helper plasmid does not contain the AAV-ITRs, the Rep and Cap genes will not be packaged. Viral particles are purified from the supernatant by CsCI, density centrifugation to separate the adenovirus from the rAAV particles, followed by heat inactivation (at 56°C) to eliminate any residual adenovirus. 1999 We have shown that vector genomes persist as high molecular weight concatamers randomly integrated into the mouse genome of liver in the form of head-to-tail tandem repeats.70 Besides integrated forms, rAAV also has been reported to persist as episomal DNA in nondividing cells. which allowed expression of the transgene. 63.71 It is likely that the process and final molecular state of the vector genome may vary. depending on species and cell type.
The integration efficiency of rAAV calculated from in vitro studies is relatively low (I to 3 X 10-4). Interestingly. the manipulation of the cellular milieu with chemical. physical, or biological stresses were shown to enhance rAAV transduction.'"".7'7h
Ultraviolet and gamma-irradiation were reported to increase rAAV transduction along with increased vector single-stranded to double-stranded DNA conver~ion,'~ whereas adenovirus coinfection were shown to enhance rAAV gene transfer in mouse liver and lung.27 This was most likely due to stimulation of the host DNA repairlsynthesis machinery, which facilitates efficient second-strand synthesis from an AAV template. In fact, second-strand DNA synthesis has been shown to be an important ratelimiting step for vector transduction.'".'7.7Un contrast to the site-specific integration of wild-type AAV in human cells. recombinant virus randomly integrates into chromosomal DNA,' 3.70.77-7Y which is due to the absence of the Rep proteins.28-"1 The process of integration in the liver will be discussed below.
The intrinsic limitations of the rAAV vector are described as follows:
1. The maximal gene insert size is about 4.5 kb, excluding larger therapeutic genes such as the dystrophin cDNA. 2. Because rAAV randomly integrates, a risk of chromosomal rearrangements or insertional mutagenesis cannot be excluded. Although insertional events resulting in transcriptional activation of cellular oncogenes or inactivation of a tumor suppressor gene are possible but infrequent.xO the effect that such an event would have on tumor susceptibility is unknown. 3 . A high percentage of humans are seropositive for anti-AAV-2 neutralizing antibodies,ll which may interfere with gene transfer. In addition. neutralizing antibodies to viral capsid proteins were shown to preclude gene transfer following readministration of rAAV vector^."^" Transient immunosuppression at the time of primary transduction has been shown to downregulate this humoral immune response and allow gene expression after repeated vector administ r a t i~n .~~ 4. Even with new packaging systems using a replication-deficient helper adenovirus in combination with the 293 packaging cell line.46 contamination with wild-type adenovirus and wild-type AAV generation cannot be completely excluded. 5. Despite recent progress toward more efficient methods. the ability to package and purify large quantities of AAV-based vectors has been limited by technical factors. Due to the transient coinfection regimen, it has generally been difficult to produce high-titer preparations, although in experienced hands high-particle titers of over I O~~l r n l of high purity have been generated. In addition, one transducing unit can consist of up to 105 virus particles, depending on the target cell type, demonstrating the relatively low basal transduction efficiency of recombinant AAV.7" Newer techniques have yielded higher titers more consistently. One of these systems is characterized by a replicating helper plasmid to express higher levels of Rep and Cup genes." Ideally, a packaging system involves both AAV and adenovirus helper functions incorporated into the same cell line. Attempts to generate AAV packaging lines by stable or inducible expression of Rep and Ccip genes have been difficult because constitutive Rep expression is cytotoxic or cytostatic to cells.x'-s-' Recently. several groups reported the production of rAAV at similar or higher titers by simplified methods with a reduced number of "hits" needed for packaging. Clark et al. generated an AAV-packaging cell line by transfecting HeLa cells with a tripartite plasmid containing the AAV coding genes, AAV vector sequences, and a Neor marker. 85 Following drug selection and infection with adenovirus, the cell line produced rAAV viral stocks at titers comparable with the transient transfection method. Alternatively, several groups have generated stable expression of episomal or integrated rAAV vector genomes in 293 packaging cells, which were subsequently transfected with helper plasmid coding for Rep and Cup and infection with adenovirus.'XJ"
The other problem is the requirement of helper adenovirus. Although the adenovirus is removed during purification, a small risk of contamination remains. Contamination with replication-competent adenovirus is not only unacceptable for gene therapy applications but also significantly influences the transduction efficiency achieved with rAAV vectors," thus complicating assessment of their utility. Recently, Maxwell et al. reported that a mutant adenovirus type 5 with the preterminal protein (pTP) gene deleted efficiently functioned as a helper for generating rAAV stocks, free from replication-competent adenovirus.*7
Plasmids containing only the essential adenovirus helper genes ( EIA, E I B 55-MI, E2A, E4orf6, and VAI RNA)"-9' have been created that successfully replaced the role of adenovirus helper virus and generated hightiter rAAV stocks completely free of adenovirus.36,'7 By transiently transfecting this plasmid in place of aden-ovirus. it was possible to obtain helper virus-free rAAV stocks with an efficiency comparable with that of standard procedures.
IN VlVO RAAV-MEDIATED GENE TRANSFER INTO THE LIVER
Recombinant adeno-associated virus vectors have been reported to transduce nondividing cells in vivo in a wide variety of tissues, including brain,',5"-53 spinal cord," eyee,SS.56 muscle,52.S7-61 lUng,62.63.h4 gUt,6? COChlea,h6 and he~irt.6~ Generally, stable and persistent gene expression was demonstrated without detectable cellular immune responses or toxicity.
The first attempt at in vivo gene transfer into the liver with rAAV vectors was reported by Wilson et 231. 27 Normal mice were infused with purified rAAV-CMVLacZ (containing the P-galactosidase reporter gene) alone (1011 particles) or combined with adenovirus into the portal circulation via the spleen. However, on day 3 after infusion, no gene expression was observed with rAAV alone (<0.01% of hepatocytes), whereas substantial enhancement of transduction occurred when combined with adenovirus (up to 25% of hepatocytes).
Miller et al. reported persistent expression of human clotting factor IX from mouse liver after intravenous injection of rAAV vectors." Although up to 3% of hepatocytes were transduced, the levels of expression were low (0.1-0.5 nglml), and this was observed only when the livers were gamma-irradiated prior to transduction and when vector stocks were contaminated with wild-type AAV.
Sugiyama et al. reported direct injection of an rAAV vector containing the insulin gene into liver parenchyma of diabetic mice." This resulted in only temporary and limited correction of hyperglycemia up to day 6 after vector administration.
Our laboratory reported the successful transduction of the liver in vivo using wild-type-free and adenovirus-free rAAV delivered as a single administration into the portal vein of normal, unmanipulated m i~e . 4~ Stable plasma concentrations of functional human factor IX in the curative range for the bleeding disorder hemophilia B were achieved with this vector, and expression persisted for at least 1 year (length of experiment). These data demonstrated the potential of treating hemophilia B by rAAV-mediated gene transfer at the natural site of factor IX production. No detectable pathology or toxicity related to the use of this vector was observed and, in contrast to adenoviral vectors, gene expression was restricted to the liver. In situ hybridization experiments for hFIX mRNA showed 3 to 5% positive hepatocytes, indicating that relatively few cells supply high levels of plasma factor IX. However, quantitative Southern analysis revealed that on average there were about three genome copies per diploid chromosome complement in the liver. Expression of factor IX levels slowly increased over a period of 1 to 5 weeks to a steady-state concentration ranging from 250 to 2000 nglml. During this early period of rising gene expression, the single-stranded AAV genomes were slowly converted to double stranded DNA.'" By performing various DNA blotting studies, the vector genomic DNA was found to exist as head-to-tail concatamers. The integrated state of the high molecular weight concatamers was confirmed by pulse-field gel electrophoresis and fluorescence in situ hybridization studies examining metaphase hepatocytes isolated from transduced mice. We estimated an average repeat size of 50 to 70 genomes per transduced cell. No episomal forms of rAAV genomes were detected, although low numbers of alternative DNA structures may not be detected by the methods used in these studies. Thus, the persistence of gene expression after rAAV gene transfer is attributed to the integration of proviral DNA.
Although the exact mechanism of single-strand to double-strand conversion is not known, these results are consistent with evidence that conversion from a single-stranded molecule to a transcriptionally active double-stranded molecule may be rate limiting for transduction.'6.17,75 Alternatively, integration57 or concatamerization of the episomal or integrated genome57. 63 .Yh may influence the rate of transduction, whereas virus internalization, virus entry, or virus uncoating were shown not to be rate limiting.26 It is not clear why integration of vector genomes was observed in only 5% of hepatocytes, when most of the cells presumably do receive vector genomes. Perhaps a threshold amount of vector genome or the presence of an as yet unknown cellular milieu is required for integration.
The slow rise of protein expression over several weeks to a steady-state level also has been described in m u s~l e ,~~~~~~~) retina," and subcutaneous tissues (Snyder et al., unpublished results) after rAAV vector administration. Molecular characterization in muscle indicates conversion of monomer vector genomes to a high molecular weight state and persistence in an integrated form, but the exact integration status of the vector into the host genome was not confirmed in these studies.f175"") If integration does occur in muscle, the mechanism may be different from that in the liver because a double-stranded circular episomal intermediate form was reported in muscle.6fl.Y' Interestingly, after in vitro gene transfer with rAAV into different human cell lines, integration occurred only in monomer f o r m~,~~~~x whereas in vivo we only observed concatermerized forms. Our data suggest that the integration events may be random, possibly via nonhomologous recombina- tion; however. further investigation is needed to sort out the structure of the junctions between cellular DNA and vector DNA.
High et al. recently confirmed our findings of in vivo gene transfer into normal mouse liver with an rAAV vector expressing human factor IX administered via the portal vein.')" Curative plasma levels of factor IX were achieved (700-3200 nglml versus 250-2000 nglml in our study), although a 3-to 12-fold higher rAAV particle dose was needed than in our studies (2.7 X 1011 versus 2.2 to 8.4 X 10lo particles/mouse). Similar to our observations. expression gradually increased to a stable level over several weeks and persisted for at least 6 months.
The low transduction observed by Wilson et al.27 with rAAV alone most likely was related to the early time point after vector administration (day 3) selected to study gene expression. As described above, we have shown that expression levels slowly rise over the first 5 weeks to a stable steady-state level. Furthermore, they used the CMV promotor. which has been shown to be downregulated when introduced into the liver.I()("(13 This has been confirmed using rAAV-mediated gene transfer into mouse l i~e r .~"~Y In the study by Sugiyama et al.,"j the follow-up time postinjection was only 6 days, which is too short to reach steady-state levels of gene expression. Importantly, no data were presented to show the proportion of transgene expressing cells in mice that received an AAV-LacZ control vector. The low expression in the in vivo experiments with rAAV expressing factor IX by Miller et al." (as described earlier) is most likely due to a suboptimal transgene-expression cassette and the lower titers of virus used for gene transfer.
FUTURE DIRECTIONS
There is considerable ongoing effort to improve on the rAAV vector system, and it is likely that there will be a number of new developments over the coming years. New developments include hybrid viruses that exploit the best of two different vectors in one. In particular, a helper-free herpes simplex viris type I (HSV-I)/AAV hybrid was shown to be superior for transduction of brain tissue than traditional HSV-I vectors. 104 Other attempts to increase transduction efficiency by producing a chimeric adenovirus/AAV hybrid vector are underway. Ultimately, methods to transiently express or deliver Rep function for site-specific integration may reduce safety issues related to random integration of DNA sequences. Russell et al. reported on a novel AAV vector that targeted DNA sequences into mammalian cells in vitro by homologous recombination, thereby replacing specific genomic sequences with exogenous DNA.lO5 This represents the first report of efficient targeted gene conversion by a viral vector and offers new hope for the treatment of genetic defects.
CONCLUSIONS
Recombinant adeno-associated virus is currently one of the most promising vectors for hepatic gene therapy, particularly for genetic diseases that require longterm transgene expression. We and others have shown that after a single administration via the portal vein of normal mice, rAAV efficiently and safely transduced quiescent hepatocytes, stably integrated into the host cell genome, and produced curative systemic levels of factor IX. Importantly, no prior manipulation of the liver or host animal was required to achieve these results. Studies are underway to confirm these data and further assess safety in larger animal models. Due to its relative safety, transduction of nondividing cells, stable integration into the host genome, and absence of an immune response that eliminates transduced cells, rAAV has a relative advantage over other existing vector systems. However, technical issues such as the inefficient rAAV production and relatively low functional titers that are obtained will need to be addressed before largescale clinical application can be realized. The most desirable characteristic of wild-type AAV, site-specific integration in chromosome 19, is lost in rAAV vectors, mainly because of the absence of viral Rep protein. Further understanding of the molecular steps involved in this process may eventually lead to targeted integration of rAAV vectors. This would not only diminish the risk of insertional mutagenesis, but also may enhance stable expression of the transgene. Despite the limited DNA insert size. which can be packaged, and potential preexisting immunity to AAV particles in humans, rAAV vectors may be currently considered as a serious candidate for potential utilization in clinical settings. Based on exciting results in preclinical animal models, the liver is expected be one of the prime targets for rAAVmediated gene therapy for many potential applications,-".l()b particularly for genetic diseases such as hemophilia.
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